UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 30

Sortiert nach

Predictors for thromboembolism in patients with cholangiocarcinoma

Journal of cancer research and clinical oncology, 2022-09, Vol.148 (9), p.2415-2426

2022

Volltextzugriff (PDF)

Expression of Amphiregulin and EGFRvIII Affect Outcome of Patients with Squamous Cell Carcinoma of the Head and Neck Receiving Cetuximab-Docetaxel Treatment

Clinical cancer research, 2011-08, Vol.17 (15), p.5197-5204

2011

Volltextzugriff (PDF)

Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer

British journal of cancer, 2018-08, Vol.119 (3), p.296-302

2018

Volltextzugriff (PDF)

VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): An Open Label Randomized Controlled Phase-2-Study

Frontiers in oncology, 2020-01, Vol.9, p.1320-1320

2020

Volltextzugriff (PDF)

Individual hematotoxicity prediction of further chemotherapy cycles by dynamic mathematical models in patients with gastrointestinal tumors

Journal of cancer research and clinical oncology, 2023-08, Vol.149 (10), p.6989-6998

2023

Volltextzugriff (PDF)

Guideline adherence and implementation of tumor board therapy recommendations for patients with gastrointestinal cancer

Journal of cancer research and clinical oncology, 2023-03, Vol.149 (3), p.1231-1240

2023

Volltextzugriff (PDF)

A diagnostic challenge of KIT p.V559D and BRAF p.G469A mutations in a paragastric mass

The oncologist (Dayton, Ohio), 2024-06

2024

Volltextzugriff (PDF)

PI3K/PTEN/AKT/mTOR polymorphisms: Association with clinical outcome in patients with head and neck squamous cell carcinoma receiving cetuximab-docetaxel

Head & neck, 2015-04, Vol.37 (4), p.471-478

2015

Volltextzugriff (PDF)

A Rare Case of Mixed Adenoneuroendocrine Carcinoma (MANEC) of the Gastroesophageal Junction with HER2/neu Overexpression and Distinct Orbital and Optic Nerve Toxicity after Intravenous Administration of Cisplatin

Oncology research and treatment, 2019-01, Vol.42 (3), p.123-127

2019

Volltextzugriff (PDF)

Leveraging Large Language Models for Decision Support in Personalized Oncology

JAMA network open, 2023-11, Vol.6 (11), p.e2343689-e2343689

2023

Volltextzugriff (PDF)

EORTC 1707 VESTIGE: Adjuvant immunotherapy in patients with resected gastric cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1)—An open-label randomized controlled phase II study

JOURNAL OF CLINICAL ONCOLOGY, 2021, Vol.39 (15_suppl), p.TPS4156-TPS4156

2021

Volltextzugriff (PDF)

Evaluation of Biomarkers for the Prediction of Venous Thromboembolism in Ambulatory Cancer Patients

Oncology research and treatment, 2020-09, Vol.43 (9), p.414-427

2020

Volltextzugriff (PDF)

The performance of three oncogeriatric screening tools - G8, optimised G8 and CARG - in predicting chemotherapy-related toxicity in older patients with cancer. A prospective clinical study

Journal of geriatric oncology, 2019-11, Vol.10 (6), p.937-943

2019

Volltextzugriff (PDF)

Association of Epidermal Growth Factor Receptor Polymorphism, Skin Toxicity, and Outcome in Patients with Squamous Cell Carcinoma of the Head and Neck Receiving Cetuximab-Docetaxel Treatment

Clinical cancer research, 2010-01, Vol.16 (1), p.304-310

2010

Volltextzugriff (PDF)

EORTC 1707 VESTIGE: Adjuvant immunotherapy in patients with resected gastric cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1): An open-label randomized controlled phase II study

JOURNAL OF CLINICAL ONCOLOGY, 2020, Vol.38 (4_suppl), p.TPS467-TPS467

2020

Volltextzugriff (PDF)

Sunitinib Treatment for Patients with Advanced Clear-Cell Renal-Cell Carcinoma after Progression on Sorafenib

Oncology, 2009-01, Vol.76 (5), p.350-354

2009

Volltextzugriff (PDF)

Pretreatment characteristics and early indicators of long-term efficacy of cetuximab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (rmSCCHN)

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.e17015-e17015

2013

Volltextzugriff (PDF)

Quality of Life of Patients with Head and Neck Cancer Receiving Cetuximab, Fluorouracil, Cisplatin Comparing to Cetuximab, Fluorouracil, Cisplatin, and Docetaxel within the CEFCID Trial

Oncology research and treatment, 2022-06, Vol.45 (6), p.319-325

2022

Volltextzugriff (PDF)

Validation of the ONKOTEV Risk Prediction Model for Venous Thromboembolism in Outpatients With Cancer

JAMA network open, 2023-02, Vol.6 (2), p.e230010-e230010

2023

Volltextzugriff (PDF)

Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients

Lung cancer (Amsterdam, Netherlands), 2007-01, Vol.55 (1), p.109-113

2007

Volltextzugriff (PDF)

Correlation between PI3K/PTEN/AKT/mTOR pathway genetic variations and clinical outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.5572-5572

2012

Volltextzugriff (PDF)

Cetuximab, fluorouracil (5-FU), cisplatin, and docetaxel as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Interim results of a randomized phase II clinical trial (CeFCiD)

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.e17021-e17021

2013

Volltextzugriff (PDF)

Risk factors for cancer-related venous thromboembolism in ambulatory patients

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.e20625-e20625

2014

Volltextzugriff (PDF)

Cetuximab (C), fluorouracil (F), and cisplatin (P) alone or with docetaxel (D) for recurrent/metastatic (RM) head and neck cancer (HNSCC): First analysis of AIO trial # 1108

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.6018-6018

2014

Volltextzugriff (PDF)

HPV and Other Risk Factors: Oropharyngeal Tumor Survival

Otolaryngology-head and neck surgery, 2011-08, Vol.145 (2_suppl), p.P168-P168

2011

Volltextzugriff (PDF)

1 – 25 von 30

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(29)
Mit Volltextzugriff
(30)

Publikationsform

Artikel
(28)
Tagungsberichte
(2)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(19)
Science & Technology
(19)
Oncology
(16)
Humans
(12)
Female
(8)
Male
(8)
Middle Aged
(8)
Aged
(6)
Antineoplastic Agents - Therapeutic Use
(4)
Chemotherapy
(4)
Hematology
(4)
Internal Medicine
(4)
Medicine
(4)
Medicine & Public Health
(4)
Patients
(4)
Prospective Studies
(4)
Treatment Outcome
(4)
Tumors
(4)
Biological And Medical Sciences
(3)
Cancer Research
(3)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Predictors for thromboembolism in patients with cholangiocarcinoma

Expression of Amphiregulin and EGFRvIII Affect Outcome of Patients with Squamous Cell Carcinoma of the Head and Neck Receiving Cetuximab-Docetaxel Treatment

Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer

VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): An Open Label Randomized Controlled Phase-2-Study

Individual hematotoxicity prediction of further chemotherapy cycles by dynamic mathematical models in patients with gastrointestinal tumors

Guideline adherence and implementation of tumor board therapy recommendations for patients with gastrointestinal cancer

A diagnostic challenge of KIT p.V559D and BRAF p.G469A mutations in a paragastric mass

PI3K/PTEN/AKT/mTOR polymorphisms: Association with clinical outcome in patients with head and neck squamous cell carcinoma receiving cetuximab-docetaxel

A Rare Case of Mixed Adenoneuroendocrine Carcinoma (MANEC) of the Gastroesophageal Junction with HER2/neu Overexpression and Distinct Orbital and Optic Nerve Toxicity after Intravenous Administration of Cisplatin

Leveraging Large Language Models for Decision Support in Personalized Oncology

EORTC 1707 VESTIGE: Adjuvant immunotherapy in patients with resected gastric cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1)—An open-label randomized controlled phase II study

Evaluation of Biomarkers for the Prediction of Venous Thromboembolism in Ambulatory Cancer Patients

The performance of three oncogeriatric screening tools - G8, optimised G8 and CARG - in predicting chemotherapy-related toxicity in older patients with cancer. A prospective clinical study

Association of Epidermal Growth Factor Receptor Polymorphism, Skin Toxicity, and Outcome in Patients with Squamous Cell Carcinoma of the Head and Neck Receiving Cetuximab-Docetaxel Treatment

EORTC 1707 VESTIGE: Adjuvant immunotherapy in patients with resected gastric cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1): An open-label randomized controlled phase II study

Sunitinib Treatment for Patients with Advanced Clear-Cell Renal-Cell Carcinoma after Progression on Sorafenib

Pretreatment characteristics and early indicators of long-term efficacy of cetuximab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (rmSCCHN)

Quality of Life of Patients with Head and Neck Cancer Receiving Cetuximab, Fluorouracil, Cisplatin Comparing to Cetuximab, Fluorouracil, Cisplatin, and Docetaxel within the CEFCID Trial

Validation of the ONKOTEV Risk Prediction Model for Venous Thromboembolism in Outpatients With Cancer

Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients

Correlation between PI3K/PTEN/AKT/mTOR pathway genetic variations and clinical outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment

Cetuximab, fluorouracil (5-FU), cisplatin, and docetaxel as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Interim results of a randomized phase II clinical trial (CeFCiD)

Risk factors for cancer-related venous thromboembolism in ambulatory patients

Cetuximab (C), fluorouracil (F), and cisplatin (P) alone or with docetaxel (D) for recurrent/metastatic (RM) head and neck cancer (HNSCC): First analysis of AIO trial # 1108

HPV and Other Risk Factors: Oropharyngeal Tumor Survival

Suchergebnisse filtern